GlassScriptPhysician profile
Julia Corbett Ronecker
NPI 1568966042
$2,116.77
in general payments reported to CMS, 2019-2025
20 companies · $1,138 in 2025
The $1,138 reported for 2025 was more than what 87% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $238 · 2024: $741 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,116.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $325.18 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $295.81 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $253.78 | 2023-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $252.68 | 2023-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $164.83 | 2023-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Corium, LLC | $106.56 | 2024-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $95.42 | 2023-2025 | Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $81.02 | 2024-2025 | Qelbree |
| Neurocrine Biosciences, INC. | $74.53 | 2025 | |
| Almatica Pharma LLC | $66.80 | 2023-2025 | Loreev Xr, Gralise |
| Abbvie INC. | $63.13 | 2025 | |
| Vanda Pharmaceuticals INC. | $62.56 | 2024-2025 | Fanapt, Hetlioz |
| Noven Therapeutics, LLC | $58.54 | 2024-2025 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $53.72 | 2024 | |
| Tris Pharma INC | $47.53 | 2025 | Dyanavel Xr |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $33.60 | 2024-2025 | Sunosi, Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.57 | 2025 | Rejoyn |
| Bausch Health US, LLC | $23.45 | 2023 | Aplenzin, Wellbutrin |
| Collegium Pharmaceutical, INC. | $18.55 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $14.51 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Ronecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.